SE9900496D0 - Vaccine formulation - Google Patents
Vaccine formulationInfo
- Publication number
- SE9900496D0 SE9900496D0 SE9900496A SE9900496A SE9900496D0 SE 9900496 D0 SE9900496 D0 SE 9900496D0 SE 9900496 A SE9900496 A SE 9900496A SE 9900496 A SE9900496 A SE 9900496A SE 9900496 D0 SE9900496 D0 SE 9900496D0
- Authority
- SE
- Sweden
- Prior art keywords
- sub
- formulation
- vaccine formulation
- sup
- adjuvant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9900496A SE9900496D0 (sv) | 1999-02-12 | 1999-02-12 | Vaccine formulation |
EP00903678A EP1150713B1 (fr) | 1999-02-12 | 2000-02-09 | Formulation de vaccin contenant des monogycerides ou des acides gras comme adjuvant |
DK00903678T DK1150713T3 (da) | 1999-02-12 | 2000-02-09 | Vaccineformulering der omfatter monoglycerider eller fedtsyrer som adjuvans |
PCT/EP2000/001038 WO2000047224A2 (fr) | 1999-02-12 | 2000-02-09 | Formulation de vaccin |
US09/926,002 US6890540B1 (en) | 1999-02-12 | 2000-02-09 | Vaccine formulation |
AU25473/00A AU769375B2 (en) | 1999-02-12 | 2000-02-09 | Vaccine formulation |
DE60019726T DE60019726T2 (de) | 1999-02-12 | 2000-02-09 | Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans |
AT00903678T ATE293993T1 (de) | 1999-02-12 | 2000-02-09 | Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans |
NZ513129A NZ513129A (en) | 1999-02-12 | 2000-02-09 | Vaccine formulation active against Mycobacterium tuberculosis bacteria containing a monoglyceride adjuvant |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9900496A SE9900496D0 (sv) | 1999-02-12 | 1999-02-12 | Vaccine formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
SE9900496D0 true SE9900496D0 (sv) | 1999-02-12 |
Family
ID=20414470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9900496A SE9900496D0 (sv) | 1999-02-12 | 1999-02-12 | Vaccine formulation |
Country Status (9)
Country | Link |
---|---|
US (1) | US6890540B1 (fr) |
EP (1) | EP1150713B1 (fr) |
AT (1) | ATE293993T1 (fr) |
AU (1) | AU769375B2 (fr) |
DE (1) | DE60019726T2 (fr) |
DK (1) | DK1150713T3 (fr) |
NZ (1) | NZ513129A (fr) |
SE (1) | SE9900496D0 (fr) |
WO (1) | WO2000047224A2 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004047862A1 (fr) * | 2002-11-26 | 2004-06-10 | Eurocine Ab | Nouvel additif a base d'amine |
US7349378B2 (en) * | 2003-02-24 | 2008-03-25 | Toshiba America Research, Inc. | Local area network resource manager |
EP1725256A4 (fr) * | 2004-02-18 | 2008-12-31 | Univ Newcastle Res Ass | Vaccin s'administrant aux muqueuses pulmonaires |
JP5159322B2 (ja) * | 2005-01-28 | 2013-03-06 | ノース−ウエスト ユニヴァーシティ | ワクチンの有効性増強のためのアジュバント |
US20090023682A1 (en) * | 2007-07-19 | 2009-01-22 | Joseph Artiss | Composition Comprising Dietary Fat Complexer and Methods of Using Same |
US8916164B2 (en) * | 2007-08-29 | 2014-12-23 | Abivax | Methods of enhancing adjuvaticity of vaccine compositions |
ES2531657T3 (es) * | 2008-05-01 | 2015-03-18 | Arecor Limited | Formulación de una proteína |
US9968666B2 (en) | 2009-06-12 | 2018-05-15 | Vaccine Technologies, Incorporated | Methods and compositions for promoting a cell-mediated immune response |
WO2010144797A2 (fr) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Vaccins contre la grippe avec immunogénicité accrue et leurs utilisations |
WO2010144794A1 (fr) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Vaccins polypeptidiques de fusion exprimés par baculovirus avec immunogénicité accrue et leurs utilisations |
CN104203275A (zh) | 2010-06-09 | 2014-12-10 | 疫苗技术股份有限公司 | 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫 |
EP3912619A1 (fr) | 2011-05-11 | 2021-11-24 | Children's Medical Center Corporation | Protéine de liaison à la biotine modifiée, leurs protéines de fusion et applications |
EP2742952A1 (fr) | 2012-12-17 | 2014-06-18 | Eurocine Vaccines AB | Composition vaccinale |
CA2900008A1 (fr) | 2013-02-07 | 2014-08-14 | Children's Medical Center Corporation | Antigenes de proteine qui conferent une protection contre une colonisation et/ou une maladie pneumococcique |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4847080A (en) * | 1984-03-07 | 1989-07-11 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers |
WO1990014837A1 (fr) * | 1989-05-25 | 1990-12-13 | Chiron Corporation | Composition d'adjuvant comprenant une emulsion de gouttelettes d'huile d'une taille inferieure au micron |
SE9601158D0 (sv) * | 1996-03-26 | 1996-03-26 | Stefan Svenson | Method of producing immunogenic products and vaccines |
SE9602280D0 (sv) * | 1996-06-10 | 1996-06-10 | Pharmatrix Ab | Immunstimulerande lipidformulering |
US6350456B1 (en) * | 1997-03-13 | 2002-02-26 | Corixa Corporation | Compositions and methods for the prevention and treatment of M. tuberculosis infection |
CA2507049A1 (fr) | 2002-11-26 | 2004-06-10 | Frost Inc. | Coussinet pour roue de chariot |
-
1999
- 1999-02-12 SE SE9900496A patent/SE9900496D0/xx unknown
-
2000
- 2000-02-09 EP EP00903678A patent/EP1150713B1/fr not_active Expired - Lifetime
- 2000-02-09 AU AU25473/00A patent/AU769375B2/en not_active Ceased
- 2000-02-09 NZ NZ513129A patent/NZ513129A/xx not_active IP Right Cessation
- 2000-02-09 US US09/926,002 patent/US6890540B1/en not_active Expired - Fee Related
- 2000-02-09 DK DK00903678T patent/DK1150713T3/da active
- 2000-02-09 WO PCT/EP2000/001038 patent/WO2000047224A2/fr active IP Right Grant
- 2000-02-09 AT AT00903678T patent/ATE293993T1/de active
- 2000-02-09 DE DE60019726T patent/DE60019726T2/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
NZ513129A (en) | 2003-01-31 |
EP1150713A2 (fr) | 2001-11-07 |
DK1150713T3 (da) | 2005-08-29 |
DE60019726D1 (de) | 2005-06-02 |
WO2000047224A2 (fr) | 2000-08-17 |
US6890540B1 (en) | 2005-05-10 |
AU769375B2 (en) | 2004-01-22 |
EP1150713B1 (fr) | 2005-04-27 |
WO2000047224A3 (fr) | 2000-12-14 |
DE60019726T2 (de) | 2006-04-27 |
AU2547300A (en) | 2000-08-29 |
ATE293993T1 (de) | 2005-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE9900496D0 (sv) | Vaccine formulation | |
CY1110140T1 (el) | Εμβολιασμος με μηνιγγοκοκκικο συζευγμα | |
EP1955709A3 (fr) | Compositions d'adjuvant d'amélioration des réponses immunitaires aux vaccins à base de polynucléotide | |
EP2272531A3 (fr) | Intégration du vaccin conjugué de méningococcus | |
JP2002501033A5 (fr) | ||
SE9600716D0 (sv) | Adhesion inhibitors, preparation comprising them and method for producing them | |
BR0111834A (pt) | Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno | |
NZ333226A (en) | Immunstimulating lipid formulation | |
IL101710A0 (en) | Transdermal formulations with increased permeation of the active substances | |
DK1154792T3 (da) | Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans | |
SE9601158D0 (sv) | Method of producing immunogenic products and vaccines | |
ATE108487T1 (de) | Herstellung eines desoxyribonucleosids. | |
SE0100011D0 (sv) | Virus vaccine formulation | |
CA2365392A1 (fr) | Preparation de vaccin contenant des acides gras comme composants | |
DE60042776D1 (de) | Lipoglykan zusammensetzungen und methoden zur behandlung von parasitischen infektionen | |
DE60024326D1 (de) | Lipide zur stimulierung der immunreaktion | |
RU99115191A (ru) | Инактивированная вакцина против ку-лихорадки |